Potential influence of more-sensitive HIV-1 load detection by the new Roche Cobas AmpliPrep/Cobas TaqMan version 2.0 assay on clinical management of HIV-positive pregnant women.
With the introduction of the new Roche Cobas AmpliPrep/Cobas TaqMan version 2.0 assay, HIV-1 viral loads will be detected more frequently during the peripartum period in pregnant HIV-positive women. The implications for the clinical management of these patients are discussed in this paper.
de Boer
M G J
MG
Department of Infectious Diseases, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, Netherlands. M.G.J.de_Boer@lumc.nl
Wessels
E
E
Claas
E C J
EC
Kroon
F P
FP
D005260:Female; D015658:HIV Infections / Q000175:diagnosis* / Q000188:drug therapy / Q000821:virology*; D015497:HIV-1 / Q000302:isolation & purification*; D006801:Humans; D025202:Molecular Diagnostic Techniques / Q000379:methods; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000175:diagnosis* / Q000821:virology*; D037841:Pregnant People; D011933:Reagent Kits, Diagnostic; D019562:Viral Load / Q000379:methods*
D011933:Reagent Kits, Diagnostic
J Acquir Immune Defic Syndr. 2007 Aug 15;45(5):483-93
17496565
Antivir Ther. 2009;14(8):1189-93
20032549
N Engl J Med. 1999 Aug 5;341(6):394-402
10432324
J Infect Dis. 2001 Feb 15;183(4):539-45
11170978
J Clin Microbiol. 2010 Apr;48(4):1195-200
20164281
J Clin Microbiol. 2009 Oct;47(10):3400-2
19656975
J Clin Virol. 2009 Sep;46(1):69-74
19576845